Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H28O2 |
| Molecular Weight | 300.4351 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
InChI
InChIKey=XWALNWXLMVGSFR-HLXURNFRSA-N
InChI=1S/C20H28O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h6,9,12,15-17,22H,4-5,7-8,10-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1
| Molecular Formula | C20H28O2 |
| Molecular Weight | 300.4351 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.steroidal.com/steroid-profiles/dianabol/Curator's Comment: description was created based on several sources, including:
Lenehan, P. (2003) "Anabolic steroids", p.101 Retrieved from https://books.google.ru/books?id=TOePv6WpruQC | https://www.healthydietadvisor.com/bodybuilding-supplements/dianabol-review/
Sources: https://www.steroidal.com/steroid-profiles/dianabol/
Curator's Comment: description was created based on several sources, including:
Lenehan, P. (2003) "Anabolic steroids", p.101 Retrieved from https://books.google.ru/books?id=TOePv6WpruQC | https://www.healthydietadvisor.com/bodybuilding-supplements/dianabol-review/
Metandienone is an orally active synthetic anabolic-androgenic steroid. In 1970, the FDA accepted that Metandienone (Dianabol) was “Probably Effective” in treating post-menopausal osteoporosis and pituitary-deficient dwarfism. Methandrostenolone is still produced today, but typically in nations with loose prescription drug regulations and by companies that still prefer to cater to an underground athletic market. Androgenic side effects are still common with this substance. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3072 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9593936 |
|||
Target ID: CHEMBL3859 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9593936 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Dianabol Approved UseIt is indicated for the treatment of post-menopausal osteoporosis and pituitary-deficient dwarfism. |
|||
| Primary | Dianabol Approved UseIt is indicated for the treatment of post-menopausal osteoporosis and pituitary-deficient dwarfism. |
Doses
| Dose | Population | Adverse events |
|---|---|---|
15 mg 1 times / day multiple, oral Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
healthy, 20-48 years |
Disc. AE: Infertility... AEs leading to discontinuation/dose reduction: Infertility (15 patients) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Infertility | 15 patients Disc. AE |
15 mg 1 times / day multiple, oral Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
healthy, 20-48 years |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Unexpected contribution of cytochrome P450 enzymes CYP11B2 and CYP21, as well as CYP3A4 in xenobiotic androgen elimination - insights from metandienone metabolism. | 2012-09-18 |
|
| The anabolic steroid methandienone targets the hypothalamic-pituitary-testicular axis and myostatin signaling in a rat training model. | 2012-01 |
|
| Chronic anabolic androgenic steroid exposure alters corticotropin releasing factor expression and anxiety-like behaviors in the female mouse. | 2010-11 |
|
| Feasibility of capillary liquid chromatography/microchip atmospheric pressure photoionization mass spectrometry in analyzing anabolic steroids in urine samples. | 2010-04-15 |
|
| Pulmonary embolism associated with protein C deficiency and abuse of anabolic-androgen steroids. | 2010-04 |
|
| CYP21-catalyzed production of the long-term urinary metandienone metabolite 17beta-hydroxymethyl-17 alpha-methyl-18-norandrosta-1,4,13-trien-3-one: a contribution to the fight against doping. | 2010-01 |
|
| Combination of liquid-chromatography tandem mass spectrometry in different scan modes with human and chimeric mouse urine for the study of steroid metabolism. | 2009-11 |
|
| Steroid metabolism in chimeric mice with humanized liver. | 2009-11 |
|
| uPA+/+-SCID mouse with humanized liver as a model for in vivo metabolism of exogenous steroids: methandienone as a case study. | 2009-10 |
|
| Humanized animal models to study drug metabolism: no longer a "chimera"? | 2009-10 |
|
| Childhood virilization and adrenal suppression after ingestion of methandienone and cyproheptadine. | 2009-05 |
|
| [Conversion of 17 alpha-methyltestosterone to methandrostenolone by the bacterium Pimelobacter simplex VKPM Ac-1632 with the presence of cyclodextrins]. | 2009-01-17 |
|
| A new mixed micellar electrokinetic chromatography method for analysis of natural and synthetic anabolic steroids. | 2009-01-15 |
|
| Oxandrolone Improves Height Velocity and BMI in Patients with Cystic Fibrosis. | 2009 |
|
| The development of multiple drug use among anabolic-androgenic steroid users: six subjective case reports. | 2008-11-28 |
|
| The dire consequences of doping. | 2008-08-23 |
|
| Detection of urinary metabolites common to structurally related 17alpha-alkyl anabolic steroids in horses and application to doping tests in racehorses: methandienone, methandriol, and oxymetholone. | 2008-06 |
|
| A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medical anabolic steroid users in the United States. | 2007-10-11 |
|
| Anabolic steroid abuse among teenage girls: an illusory problem? | 2007-05-11 |
|
| A downscaled multi-residue strategy for detection of anabolic steroids in bovine urine using gas chromatography tandem mass spectrometry (GC-MS3). | 2007-03-14 |
|
| High amounts of 17-methylated anabolic-androgenic steroids in effervescent tablets on the dietary supplement market. | 2007-02 |
|
| [Main symptom jaundice--differential diagnosis at the bedside]. | 2007-01-15 |
|
| Doping control for metandienone using hair analyzed by gas chromatography-tandem mass spectrometry. | 2006-05-19 |
|
| Collision-induced dissociation pathways of anabolic steroids by electrospray ionization tandem mass spectrometry. | 2006-04 |
|
| Research of stimulants and anabolic steroids in dietary supplements. | 2006-02 |
|
| Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine. | 2006 |
|
| Detection, quantification and confirmation of anabolic steroids in equine plasma by liquid chromatography and tandem mass spectrometry. | 2005-12-27 |
|
| Separation and online preconcentration by multistep stacking with large-volume injection of anabolic steroids by capillary electrokinetic chromatography using charged cyclodextrins and UV-absorption detection. | 2005-11 |
|
| Dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, gamma-hydroxybutyrate, and anabolic steroids. | 2005-05 |
|
| Screening of anabolic steroids in horse urine by liquid chromatography-tandem mass spectrometry. | 2005-04-29 |
|
| Anabolic-androgenic steroid interaction with rat androgen receptor in vivo and in vitro: a comparative study. | 2005-04 |
|
| Steroids' transformations in Penicillium notatum culture. | 2005-03 |
|
| Validation of a GC-MS screening method for anabolizing agents in aqueous nutritional supplements. | 2005-01 |
|
| Myocardial infarction with intracoronary thrombus induced by anabolic steroids. | 2004-12 |
|
| [Acute myocardial infarction in a young man who had been using androgenic anabolic steroids]. | 2004-01-22 |
|
| [Assessment of mutagenic danger of food products]. | 2004 |
|
| [Severe nephrotic syndrome in a young man taking anabolic steroid and creatine long term]. | 2003-12-07 |
|
| Glucuronidation of anabolic androgenic steroids by recombinant human UDP-glucuronosyltransferases. | 2003-09 |
|
| Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. | 2003-06 |
|
| [Coronary thrombosis and ectasia of coronary arteries after long-term use of anabolic steroids]. | 2003-04 |
|
| Chronic administration of anabolic steroids disrupts pubertal onset and estrous cyclicity in rats. | 2003-02 |
|
| Practical uses for ecdysteroids in mammals including humans: an update. | 2003 |
|
| [Hepatoprotective effects of silymarin in androgenic-anabolic steroid-induced liver damage]. | 2003 |
|
| Coronary thrombus in a 23 year old anabolic steroid user. | 2002-10 |
|
| [Cholestatic jaundice and pruritus]. | 2002-09-18 |
|
| [Comparative study of anabolizing activity of apilac and methandrostenolone on a model of isolated overload of the rat skeletal muscle]. | 2002-05-25 |
|
| Bleeding oesophageal varices associated with anabolic steroid use in an athlete. | 1990-10 |
|
| Hypoplastic anemia associated with metolazone. | 1979-07-13 |
|
| Experimental progressive muscular dystrophy and its treatment with high doses anabolizing agents. | 1978-04 |
|
| Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. | 1972-12-16 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23675320
Cell death was evaluated by staining PC12 cells treated for 48 h with 75 uM methandienone. Methandienone is toxic to neurons, inducing death in treated cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:33:27 GMT 2025
by
admin
on
Mon Mar 31 17:33:27 GMT 2025
|
| Record UNII |
COZ1R7EOCC
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QA14AA03
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
||
|
DEA NO. |
4000
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
||
|
WHO-ATC |
A14AA03
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
||
|
WHO-ATC |
D11AE01
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
||
|
LIVERTOX |
613
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
||
|
WIKIPEDIA |
Designer-drugs-Methandrostenolone
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
||
|
NCI_THESAURUS |
C2360
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
||
|
WHO-VATC |
QD11AE01
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1734
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
72-63-9
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
3360
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
CHEMBL1418176
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
COZ1R7EOCC
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
METHANDROSTENOLONE
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
D008696
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
100000089098
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
983
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
m7293
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB13586
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
C87589
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
DTXSID2023276
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
SUB08812MIG
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
6300
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
42722
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
6818
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | RxNorm | ||
|
200-787-2
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |